Company News »

Genocea to Present at the Stifel Nicolaus 2014 Healthcare Conference

Business Wire
Share on StockTwits
Published on

Genocea Biosciences, Inc. (NASDAQ:GNCA) , a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at the Stifel Nicolaus 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 19, 2014 at 10:20 a.m. EST in New York, NY.

A live webcast of the presentation can be accessed by visiting the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.

About Genocea
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLASTM, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea’s pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company’s website at www.genocea.com.

Share on StockTwits